Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Saved in:
Bibliographic Details
Title: Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
Authors: Ogbogu PU; Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Roufosse F; Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Site Erasme, Université Libre de Bruxelles, Brussels, Belgium., Akuthota P; Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Kuna P; Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland., Groh M; Universtié de Versailles Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France; National Referral Center for Hypereosinophilic Syndromes, Department of Internal Medicine, Clinical Immunology and Hematology, Hôpital Foch, Suresnes, France., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Yokota A; Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan., Siddiqui SH; NIHR Imperial Biomedical Research Centre, National Heart and Lung Institute, Royal Brompton and Hammersmith Hospitals, Imperial College London, London, UK., Mutsaers PGNJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands., Li B; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Khoury P; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Bahadori LM; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bednarczyk A; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland., Bouma G; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Brooks LG; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ferreira J; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Grindebacke H; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ho CN; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jain P; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Palmer RL; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jison ML; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Klion AD; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. amy.klion@nih.gov.
Corporate Authors: NATRON study group
Source: Nature medicine [Nat Med] 2026 Jun; Vol. 32 (6), pp. 2319.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-026-04425-3